MarketCapExport financials
Oramed Pharmaceuticals (ORMP)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Oramed Pharmaceuticals Income Statement 2025-2002 | ORMP
Brief overview of income trends at Oramed Pharmaceuticals
The comparison covers a five-year financial horizon. Revenue at Oramed Pharmaceuticals moved from 2.7 million dollars in 2020 to 2 million dollars in 2025. Across the full period, sales moved by −26.2%; the average annual rate was −5.9%. The business finished the period with a smaller revenue base.
Gross profit changed from 2.7 million dollars to 13 thousand dollars (−99.5%). Comparing the endpoints gives gross margins of 100% and 0.7%. The business retained less gross profit from each unit of revenue.
The operating result measured by EBITDA moved from −$11.8 million to −$15 million, or −27.4%. There was no major divergence between EBITDA and revenue. At the operating-margin level, the figure shifted from −433.6% to −748.4%. Operating return per unit of revenue declined.
Comparing the endpoints shows a move from −$11.5 million to $64 million. The business moved out of a loss and ended the period with a profit.
What the figures show
The indicators point to a weaker financial profile. The constructive conclusion rests on improving net profitability. The overall view is constrained by a low gross margin, a narrow EBITDA buffer and weak sales momentum. The next reporting periods will show whether revenue, margins, and final profitability can strengthen.
Annual Income Statement Oramed Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2002 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
137 M | 136 M | 117 M | 85 M | 255 M | 60.6 M | 55.7 M | 72.5 M | 132 M | 91.7 M | 59.2 M | 75.2 M | 44.8 M | 22.6 M | 22.7 M | - | - | - | - | - |
Shares |
41.4 M | 40.9 M | 40.3 M | 39 M | 28.5 M | 23.2 M | 17.5 M | 14.9 M | 13.3 M | 12.6 M | 10.8 M | 9.24 M | 7.21 M | 5.88 M | 5.42 M | - | - | - | - | - |
Historical Prices |
3.32 | 3.32 | 2.89 | 2.18 | 8.96 | 7.26 | 5.23 | 3.15 | 8.14 | 6.55 | 6.4 | 5.04 | 22.1 | 7.39 | 3.6 | 6.12 | 6 | 8.28 | 7.56 | - |
Net Income |
64 M | -19.1 M | 5.09 M | -36.6 M | -12.3 M | -11.5 M | -14.4 M | -12.7 M | -10.5 M | -11 M | -7.23 M | -5.7 M | -4.23 M | -3.34 M | -1.56 M | -2.98 M | -2.76 M | -2.77 M | -4.48 M | - |
Revenue |
2 M | - | 1.34 M | 2.7 M | 2.7 M | 2.71 M | 2.7 M | 2.45 M | 2.46 M | 641 K | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
1.99 M | - | - | - | - | - | 90 K | -86 K | 187 K | 490 K | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
13 K | - | - | - | - | 2.71 M | 2.61 M | 2.54 M | 2.27 M | 151 K | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-15.1 M | -12.8 M | -15.8 M | -40.6 M | -24.2 M | -11.8 M | -14.6 M | -13.5 M | -10.8 M | -10 M | -7.38 M | -5.91 M | 4.3 M | -2.88 M | -2.44 M | - | - | - | - | - |
Interest Expense |
-606 K | -27 K | 2.04 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-15 M | -12.6 M | -15.6 M | -40.5 M | -24.2 M | -11.8 M | -14.6 M | -13.5 M | -10.8 M | -10 M | -7.38 M | -5.9 M | -4.3 M | -2.87 M | -2.41 M | - | - | - | - | - |
Operating Expenses |
- | - | - | - | - | 14.5 M | 17.2 M | 16.1 M | 13 M | 10.2 M | 7.38 M | 5.91 M | 4.3 M | 2.88 M | 2.44 M | - | - | - | - | - |
General and Administrative Expenses |
8.72 M | 6.46 M | 8.42 M | 13.8 M | - | 4.23 M | 3.72 M | 4.08 M | 2.76 M | 2.45 M | 2.6 M | 2.63 M | 2.03 M | 1.2 M | 1.28 M | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement Oramed Pharmaceuticals
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
41.7 M | 40.8 M | - | 41.8 M | 41.7 M | 41.2 M | 39.9 M | 40.9 M | 41 M | 40.8 M | 40.3 M | 40.4 M | 40.2 M | 40 M | 39.6 M | 39.1 M | 38.8 M | 38.7 M | 38.2 M | 34.5 M | 30.7 M | 28 M | 24.4 M | 19.5 M | 23.2 M | 23.7 M | 17.5 M | 17.5 M | 17.5 M | 17.5 M | 17.4 M | 14.4 M | 14.5 M | 17.4 M | 14.2 M | 13.3 M | 13.3 M | 14.2 M | 13.2 M | 12.5 M | 13.1 M | 13.2 M | 11.6 M | 10.6 M | 10.8 M | 11.6 M | 10.1 M | 8.99 M | 9.89 M | 10.1 M | 7.94 M | 7.09 M | 7.22 M | 7.94 M | 6.83 M | 5.85 M | 5.86 M | 5.85 M | 70.1 M | 70.1 M | 70.1 M | 70.1 M |
Net Income |
13.3 M | 38.3 M | - | 48.4 M | 13.3 M | -7.64 M | - | -19.6 M | 9.21 M | 1.54 M | - | -3.22 M | -1.19 M | -3.4 M | - | -7.06 M | -10.5 M | -10.7 M | -12.3 M | -7.54 M | -3.91 M | -8.1 M | -7.32 M | -8.52 M | -2.28 M | -5.57 M | -2.54 M | 12.1 M | 4.07 M | -2.54 M | -4.3 M | -9.8 M | -4.35 M | -4.3 M | -2.53 M | -7.78 M | -1.96 M | -2.53 M | -2.64 M | 6.2 M | 2 M | -2.64 M | -2.39 M | -5.12 M | -1.58 M | -2.39 M | -1.9 M | 4.07 M | 1.83 M | -1.9 M | -1.12 M | -3.44 M | -4.23 M | -1.12 M | -959 K | -3.34 M | -3.34 M | -959 K | -479 K | -1.56 M | -1.56 M | -479 K |
Revenue |
- | 2 M | - | - | - | 2 M | - | - | - | - | - | - | 674 K | 666 K | - | 682 K | 674 K | 666 K | 904 K | 682 K | 674 K | 674 K | 904 K | 2.03 M | 681 K | 674 K | 674 K | 2.02 M | 682 K | 674 K | 674 K | 1.83 M | 617 K | 674 K | 611 K | 1.84 M | 617 K | 611 K | 610 K | -288 K | -163 K | -610 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
- | 1.99 M | - | - | - | 1.99 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 90 K | 90 K | 55 K | 35 K | -86 K | -86 K | 35 K | - | 187 K | 187 K | - | 187 K | -12 K | -8 K | -187 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
- | 13 K | - | - | - | 13 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-2.49 M | -3.66 M | - | -2.43 M | -2.49 M | -4.5 M | - | -3.09 M | -3.14 M | -2.96 M | - | -2.89 M | -3.79 M | -5.21 M | - | -8.19 M | -11.4 M | -11.3 M | -12.3 M | -7.48 M | -4.45 M | -8.06 M | -7.56 M | -8.74 M | -2.27 M | -5.83 M | -2.43 M | -12.3 M | -4.08 M | -2.43 M | -4.64 M | -10.4 M | -4.53 M | -4.64 M | -2.73 M | -7.92 M | -2.16 M | -2.73 M | -2.4 M | 6.47 M | 2.11 M | 2.4 M | 2.45 M | -5.21 M | -1.63 M | -2.45 M | -1.9 M | 4.26 M | 1.9 M | -1.9 M | -1.17 M | -3.33 M | -1.33 M | -1.17 M | -732 K | -1.95 M | -540 K | -732 K | -466 K | -1.84 M | -591 K | -466 K |
Interest Expense |
-4 K | -100 K | - | - | - | -3.62 M | - | - | - | 3.55 M | - | 826 K | - | - | - | - | - | - | - | - | - | 260 K | 257 K | - | 235 K | 349 K | -114 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-2.49 M | -3.63 M | - | - | - | -4.47 M | - | - | - | -2.91 M | - | - | - | -5.17 M | - | -8.15 M | -11.4 M | -11.2 M | -12.3 M | -7.42 M | -4.4 M | -8.05 M | -7.55 M | -8.74 M | -2.27 M | -5.82 M | -2.43 M | -12.3 M | -4.07 M | -2.43 M | -4.64 M | -10.4 M | -4.53 M | -4.64 M | -2.73 M | -7.91 M | -2.15 M | -2.73 M | -2.4 M | 6.47 M | 2.11 M | 2.4 M | 2.45 M | -5.21 M | -1.63 M | -2.45 M | -1.9 M | 4.26 M | 1.91 M | -1.9 M | -1.17 M | -3.32 M | -1.33 M | -1.04 M | -730 K | -1.93 M | -529 K | -730 K | -460 K | -1.82 M | -576 K | -460 K |
Operating Expenses |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 201 K | 190 K | 143 K | 109 K | 198 K | 186 K | 67 K | 92 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
1.46 M | 2.06 M | - | 1.27 M | 1.46 M | 2.31 M | - | 847 K | 1.69 M | 1.78 M | - | 2.6 M | 2.45 M | 1.26 M | - | 3.06 M | 2.53 M | 5.49 M | 3.3 M | 1.91 M | 1.93 M | 1.74 M | 1.58 M | 3.5 M | 1.03 M | 727 K | 1.08 M | 2.9 M | 899 K | 1.08 M | 932 K | 3.05 M | 1.04 M | 932 K | 1.02 M | 1.82 M | 505 K | 1.02 M | 468 K | -1.83 M | -555 K | -468 K | -548 K | 1.86 M | 719 K | 548 K | 600 K | -1.74 M | -814 K | 600 K | 418 K | 1.35 M | 499 K | 418 K | 339 K | 802 K | 291 K | 339 K | 282 K | 971 K | 350 K | 282 K |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company Oramed Pharmaceuticals (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Canada
Britain
USA
Danmark
China
Cayman-islands
